{"id":52505,"date":"2025-08-31T18:38:34","date_gmt":"2025-08-31T22:38:34","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/stada-pivots-to-ipo-after-e10-billion-capvest-acquisition-talks-collapse\/52505\/"},"modified":"2025-08-31T18:38:34","modified_gmt":"2025-08-31T22:38:34","slug":"stada-pivots-to-ipo-after-e10-billion-capvest-acquisition-talks-collapse","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/stada-pivots-to-ipo-after-e10-billion-capvest-acquisition-talks-collapse\/52505\/","title":{"rendered":"Stada Pivots to IPO After \u20ac10 Billion CapVest Acquisition Talks Collapse"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>CapVest Partners&#39;<\/strong> proposed <strong>\u20ac10 billion<\/strong> acquisition of German drugmaker <strong>Stada Arzneimittel<\/strong> has reportedly collapsed, with discussions faltering over differences in valuation and bid structure.<\/li>\n<li><strong>Stada&#39;s<\/strong> private equity owners, <strong>Bain Capital<\/strong> and <strong>Cinven<\/strong>, are now actively resuming preparations for an <strong>Initial Public Offering (IPO)<\/strong>, which could take place as early as <strong>October 2025<\/strong>.<\/li>\n<li>The potential sale to <strong>CapVest<\/strong> would have marked one of Europe&#39;s largest private equity transactions of 2025, but the renewed focus on an IPO signals a significant shift in exit strategy.<\/li>\n<li><strong>Stada<\/strong>, a leading producer of generic and over-the-counter medicines, reported <strong>\u20ac2.12 billion<\/strong> in revenue for the first half of 2025 and expects 2025 adjusted EBITDA between <strong>\u20ac930 million and \u20ac990 million<\/strong>.<\/li>\n<\/ul>\n<h2>Stalled Acquisition Talks Lead to IPO Revival<\/h2>\n<p>London-based private equity firm <strong>CapVest Partners<\/strong> was in advanced discussions to acquire a majority stake in German pharmaceutical company <strong>Stada Arzneimittel<\/strong>, a deal that could have valued the business at approximately <strong>\u20ac10 billion<\/strong> including debt. However, these negotiations have reportedly stalled or broken down, primarily due to disagreements over valuation and the structure of the proposed bid. This development potentially ends a long-running saga to sell the German drugmaker.<\/p>\n<p>Following the breakdown of talks with <strong>CapVest<\/strong>, <strong>Stada&#39;s<\/strong> current owners, private equity firms <strong>Bain Capital<\/strong> and <strong>Cinven<\/strong>, are now pivoting back to an <strong>Initial Public Offering (IPO)<\/strong>. Preparations for a listing are reportedly resuming, with an IPO potentially occurring as early as <strong>October 2025<\/strong>. This marks a significant shift, as an IPO has long been considered an alternative exit strategy for <strong>Bain Capital<\/strong> and <strong>Cinven<\/strong>.<\/p>\n<h2>Stada&#39;s Ownership History and Business Profile<\/h2>\n<p><strong>Bain Capital<\/strong> and <strong>Cinven<\/strong> acquired <strong>Stada<\/strong> in 2017 for <strong>\u20ac5.3 billion<\/strong>, taking the company private from the Frankfurt Stock Exchange. Since then, <strong>Stada<\/strong> has expanded through several acquisitions, solidifying its position as a major European producer of generic drugs, over-the-counter (OTC) healthcare products, and specialty medicines for rare and chronic conditions. Its well-known brands include <strong>Grippostad<\/strong> for cold and flu treatment and <strong>Hirudoid cream<\/strong> for bruises.<\/p>\n<p>The company had previously explored an IPO in March 2025 but paused those plans due to market volatility stemming from geopolitical events. The renewed push for a public listing underscores the owners&#39; determination to find an exit for their investment.<\/p>\n<h2>Financial Performance and Market Context<\/h2>\n<p><strong>Stada<\/strong> reaffirmed its 2025 financial targets in June, projecting adjusted EBITDA between <strong>\u20ac930 million and \u20ac990 million<\/strong> on revenues of <strong>\u20ac4.25 billion to \u20ac4.4 billion<\/strong>. In the first half of 2025, the company reported strong performance with 6% year-over-year revenue growth, reaching <strong>\u20ac2.12 billion<\/strong>. This growth was partly attributed to the July 2024 launch of Uzpruvo, a biosimilar to Johnson &amp; Johnson&#39;s Stelara, developed in partnership with Alvotech.<\/p>\n<p>The generic and OTC drug market continues to attract significant interest from private equity firms due to its stable cash flows. While the <strong>CapVest<\/strong> deal would have been one of the largest European pharma transactions of the year, the focus now shifts to how <strong>Stada&#39;s<\/strong> potential IPO will be received by the market and what valuation it might achieve as a publicly traded entity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways CapVest Partners&#39; proposed \u20ac10 billion acquisition of German drugmaker Stada Arzneimittel has reportedly collapsed, with discussions faltering over [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[9706,3829,4147,5681,5997,7135,9702,9703,9704,9705],"class_list":["post-52505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-otc","tag-ma","tag-ipo","tag-private-equity","tag-pharma","tag-bain-capital","tag-generics","tag-stada","tag-capvest","tag-cinven"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=52505"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52505\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=52505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=52505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=52505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}